<DOC>
	<DOCNO>NCT00024310</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Folic acid may protect normal cell side effect chemotherapy may increase effectiveness chemotherapy make tumor cell sensitive drug . Lometrexol may stop growth tumor block one enzymes necessary cancer cell growth . Combining chemotherapy folic acid lometrexol may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine paclitaxel , folic acid , lometrexol treat patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Paclitaxel , Folic Acid , Lometrexol Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II study dose lometrexol paclitaxel combine folic acid patient locally advance metastatic solid tumor . - Determine quantitative qualitative toxic effect regimen patient . - Determine plasma concentration lometrexol paclitaxel relate pharmacokinetics toxicity outcome patient . - Determine antitumor activity regimen patient . OUTLINE : This multicenter , dose-escalation study lometrexol paclitaxel . Patients receive lometrexol IV 30-60 second immediately follow paclitaxel IV 3 hour day 1 . Patients also receive oral folic acid begin 7 day lometrexol/paclitaxel continue 14 day . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Doses lometrexol paclitaxel escalate sequentially . Cohorts 3-6 patient receive escalate dos lometrexol paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose-limiting toxicity . Six twelve additional patient treat recommended phase II study dose ( dose immediately precede MTD ) . Patients follow every 3 month . PROJECTED ACCRUAL : Approximately 12-42 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lometrexol</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven locally advanced metastatic solid tumor refractory standard therapy therapies potential major benefit Measurable disease No hematologic malignancy , include leukemia , lymphoma , multiple myeloma No symptomatic effusion ascites unless drain study entry No clinically apparent CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 01 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3* Platelet count least 100,000/mm^3* Hemoglobin least 9.0 g/dL* NOTE : * Without growth factor support Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN tumor involvement liver ) Albumin great 2.5 g/dL Renal : Glomerular filtration rate least 65 mL/min Gastrointestinal : No inflammatory bowel disease No radiation enteritis No malabsorption syndrome Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity study drug relate compound ( e.g. , LY309887 , multitargeted antifolate , AG2034 , methotrexate , docetaxel , polyoxyethylated castor oil ) No active uncontrolled infection unless approve investigator No severe concurrent disease would preclude study therapy No body surface area great 3.0 m^2 No known vitamin B12 deficiency PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent routine prophylactic filgrastim ( GCSF ) , sargramostim ( GMCSF ) , epoetin alfa No concurrent biologicresponse modifier Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin , carboplatin , nitrosourea ) recover No concurrent cytotoxic chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : Recovered prior radiotherapy No prior radiotherapy 25 % bone marrow ( e.g. , wholepelvic irradiation ) No concurrent radiotherapy ( include palliative radiotherapy ) Surgery : At least 4 week since prior major surgery recover Other : At least 4 week since prior investigational agent No 2 prior therapy locally advance metastatic solid tumor No concurrent investigational agent No concurrent trimethoprim , cotrimoxazole , proguanil , pyrimethamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>